Corticotropin releasing factor receptor antagonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11007201
APP PUB NO 20210038609A1
SERIAL NO

17078054

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SPRUCE BIOSCIENCES INC548 MARKET STREET SUITE 74589 SAN FRANCISCO CA 94105

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gerber, Hal San Francisco, US 14 82
Howerton, Alexis San Francisco, US 14 82
Huang, Michael San Francisco, US 62 1596

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 18, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 18, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00